Panacea Biotec Limited (PANACEABIO.NS)

INR 544.6

(-1.37%)

EBITDA Summary of Panacea Biotec Limited

Panacea Biotec Limited's latest annual EBITDA in 2023 was -47.58 Million INR , up 56.67% from previous year.
Panacea Biotec Limited's latest quarterly EBITDA in 2024 Q1 was -139.9 Million INR , down -199.2% from previous quarter.
Panacea Biotec Limited reported an annual EBITDA of 563.65 Million INR in 2022, down -1386.83% from previous year.
Panacea Biotec Limited reported an annual EBITDA of 16.73 Billion INR in 2021, down -103.59% from previous year.
Panacea Biotec Limited reported a quarterly EBITDA of N/A for 2023 FY, up 56.67% from previous quarter.
Panacea Biotec Limited reported a quarterly EBITDA of -42.3 Million INR for 2023 Q1, down -145.05% from previous quarter.

Annual EBITDA Chart of Panacea Biotec Limited (2023 - 2004)

Historical Annual EBITDA of Panacea Biotec Limited (2023 - 2004)

Year	EBITDA	EBITDA Growth
2023	-47.58 Million INR	56.67%
2022	563.65 Million INR	-1386.83%
2021	16.73 Billion INR	-103.59%
2020	866.06 Million INR	-4.04%
2019	456.49 Million INR	209.65%
2018	2.07 Billion INR	-192.97%
2017	941.25 Million INR	-20.48%
2016	1.16 Billion INR	-13.79%
2015	1.81 Billion INR	99.77%
2014	723.6 Million INR	125.78%
2013	1.1 Billion INR	-211.86%
2012	-676.5 Million INR	-226.49%
2011	-1.14 Billion INR	-108.75%
2010	2.82 Billion INR	27.22%
2009	2.2 Billion INR	796.63%
2008	245.48 Million INR	-90.1%
2007	2.49 Billion INR	-6.5%
2006	2.66 Billion INR	102.42%
2005	1.31 Billion INR	90.5%
2004	703.19 Million INR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-139.9 Million INR	-199.2%
2023 FY	- INR	56.67%
2023 Q1	-42.3 Million INR	-145.05%
2023 Q2	-3.3 Million INR	92.2%
2023 Q3	-1.5 Million INR	54.55%
2023 Q4	-60.4 Million INR	-3926.67%
2022 Q2	66.1 Million INR	109.78%
2022 Q4	93.9 Million INR	-57.03%
2022 FY	- INR	-1386.83%
2022 Q1	-676 Million INR	-104.1%
2022 Q3	218.5 Million INR	230.56%
2021 Q4	16.49 Billion INR	12097.17%
2021 FY	- INR	-103.59%
2021 Q3	135.2 Million INR	67.95%
2021 Q1	16.8 Million INR	-69.35%
2021 Q2	80.5 Million INR	379.17%
2020 FY	- INR	-4.04%
2020 Q4	54.82 Million INR	-67.73%
2020 Q3	169.9 Million INR	-57.61%
2020 Q2	400.8 Million INR	68.47%
2020 Q1	237.9 Million INR	1.46%
2019 Q2	-25.2 Million INR	-108.85%
2019 Q3	401.4 Million INR	1692.86%
2019 Q4	234.48 Million INR	-41.58%
2019 FY	- INR	209.65%
2019 Q1	284.8 Million INR	142.9%
2018 Q4	-663.8 Million INR	-359.6%
2018 Q2	-81.4 Million INR	36.11%
2018 Q1	-127.4 Million INR	0.0%
2018 FY	- INR	-192.97%
2018 Q3	255.7 Million INR	414.13%
2017 FY	- INR	-20.48%
2016 FY	- INR	-13.79%
2015 FY	- INR	99.77%
2014 FY	- INR	125.78%
2013 FY	- INR	-211.86%
2012 FY	- INR	-226.49%
2011 FY	- INR	-108.75%
2010 FY	- INR	27.22%
2009 FY	- INR	796.63%
2008 FY	- INR	-90.1%
2007 FY	- INR	-6.5%
2006 FY	- INR	102.42%
2005 FY	- INR	90.5%
2004 FY	- INR	0.0%

Peer EBITDA Comparison of Panacea Biotec Limited

Name	EBITDA	EBITDA Difference
Biocon Limited	41.52 Billion INR	100.115%
Blue Jet Healthcare Limited	2.29 Billion INR	102.076%
Concord Biotech Limited	4.65 Billion INR	101.021%
Dishman Carbogen Amcis Limited	3.07 Billion INR	101.549%
Jubilant Ingrevia Limited	4.56 Billion INR	101.042%
Lyka Labs Limited	167.58 Million INR	128.391%
Piramal Pharma Limited	13.05 Billion INR	100.364%
SMS Lifesciences India Limited	349.41 Million INR	113.617%
Supriya Lifescience Limited	1.83 Billion INR	102.592%
Syngene International Limited	10.84 Billion INR	100.439%
TAKE Solutions Limited	-1.05 Billion INR	95.472%
Zota Health Care Limited	82.07 Million INR	157.973%